SMU-L11 is a specific TLR7 agonist (EC50=0.024 µM), which recruits MyD88 adapter protein and activates downstream NF-kappaB and MAPK signaling pathways. In murine models, SMU-L11 significantly enhances immune cell activation and promotes the proliferation of CD4+ T and CD8+ T cells, thereby directly killing tumor cells and inhibiting tumor growth. SMU-L11 can be used for cancer research, and also has the potential for studying immune system diseases[1].
Molecular Weight:
324.42
Purity:
99.64
Formula:
C19H24N4O
Target:
MAPKAPK2 (MK2),NF-kappaB,Toll-like Receptor (TLR)
Application Notes:
MCE Product type: Reference compound1
* VAT and and shipping costs not included. Errors and price changes excepted
